Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2004;43:186-191
Published online before print January 12, 2004, doi: 10.1161/01.HYP.0000112424.06921.52
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/2/186    most recent
01.HYP.0000112424.06921.52v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Summar, M. L.
Right arrow Articles by Brown, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Summar, M. L.
Right arrow Articles by Brown, N. J.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*OMIM
*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-ARGININE
*NITRIC OXIDE
*UREA
*Genetics Home Reference
Related Collections
Right arrow Clinical genetics
Right arrow Endothelium/vascular type/nitric oxide

(Hypertension. 2004;43:186.)
© 2004 American Heart Association, Inc.


Scientific Contributions

Relationship Between Carbamoyl-Phosphate Synthetase Genotype and Systemic Vascular Function

Marshall L. Summar; James V. Gainer; Mias Pretorius; Hector Malave; Stephanie Harris; Lynn D. Hall; Alec Weisberg; Douglas E. Vaughan; Brian W. Christman; Nancy J. Brown

From the Department of Pediatrics, Division of Medical Genetics (M.L.S., S.H., L.D.H.); the Department of Medicine, Divisions of Clinical Pharmacology (J.V.G., A.W., N.J.B.), Pulmonary Medicine (B.W.C.), and Cardiovascular Medicine (H.M., D.E.V.); and the Department of Anesthesia (M.P.), Vanderbilt University Medical Center, Nashville, Tenn.

Correspondence to Nancy J. Brown, MD, 560 Robinson Research Building, Vanderbilt University Medical Center, Nashville, TN 37232-6602. E-mail nancy.j.brown{at}vanderbilt.edu

Endothelial cells can convert L-citrulline to L-arginine, the precursor of nitric oxide. The present study tests the hypothesis that a C-to-A nucleotide transversion (T1405N) in the gene-encoding carbamoyl-phosphate synthetase 1, the enzyme catalyzing the rate-limiting step in L-citrulline formation, influences nitric oxide metabolite concentrations or nitric oxide-mediated vasodilation in humans. Bradykinin (100, 200, and 400 ng/min) was infused via brachial artery in 106 (CC:AC:AA=40:54:12) healthy subjects. Sodium nitroprusside (1.6, 3.2, and 6.4 µg/min) was also infused in 87 (CC:AC:AA=31:46:10) subjects. Forearm blood flow was measured by plethysmography and blood samples were collected for tissue-type plasminogen activator antigen, nitric oxide metabolites, and cyclic GMP. There was a significant relationship between carbamoyl-phosphate synthetase 1 genotype and nitric oxide metabolites, such that nitric oxide metabolite concentrations were highest in individuals homozygous for the C allele (mean±SD, 14.0±8.5 µmol/L), lowest in individuals homozygous for the A allele (9.1±3.1 µmol/L), and intermediate (11.8±6.6 µmol/L) in heterozygotes (P=0.036). There was a significant effect of carbamoyl-phosphate synthetase 1 genotype on forearm blood flow during bradykinin (P=0.028), such that the vasodilator response was greatest in C allele homozygotes (22.2±9.1 mL/min/100 mL at 400 ng/min), least in A allele homozygotes (13.6±6.2 mL/min/100 mL), and intermediate (19.4±10.7 mL/min/100 mL) in heterozygotes. Similarly, carbamoyl-phosphate synthetase 1 genotype influenced forearm blood flow during nitroprusside (maximal flow 19.2±8.3, 18.1±8.3, and 11.5±4.9 mL/min/100 mL in the CC:AC:AA groups, respectively; P=0.022). In contrast, there was no effect of carbamoyl-phosphate synthetase 1 genotype on the nitric oxide–independent tissue-type plasminogen activator response to bradykinin (P=0.943). These data indicate that a polymorphism in the gene encoding carbamoyl-phosphate synthetase 1 influences nitric oxide production as well as vascular smooth muscle reactivity.


Key Words: nitric oxide • bradykinin • genetics • endothelium • vasodilation




This article has been cited by other articles:


Home page
Circ Cardiovasc GenetHome page
G. Pare, D. I. Chasman, A. N. Parker, R. R.Y. Zee, A. Malarstig, U. Seedorf, R. Collins, H. Watkins, A. Hamsten, J. P. Miletich, et al.
Novel Associations of CPS1, MUT, NOX4, and DPEP1 With Plasma Homocysteine in a Healthy Population: A Genome-Wide Evaluation of 13 974 Participants in the Women's Genome Health Study
Circ Cardiovasc Genet, April 1, 2009; 2(2): 142 - 150.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc GenetHome page
J. S. Danik, G. Pare, D. I. Chasman, R. Y.L. Zee, D. J. Kwiatkowski, A. Parker, J. P. Miletich, and P. M Ridker
Novel Loci, Including Those Related to Crohn Disease, Psoriasis, and Inflammation, Identified in a Genome-Wide Association Study of Fibrinogen in 17 686 Women: The Women's Genome Health Study
Circ Cardiovasc Genet, April 1, 2009; 2(2): 134 - 141.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
F. Scaglia, N. Brunetti-Pierri, S. Kleppe, J. Marini, S. Carter, P. Garlick, F. Jahoor, W. O'Brien, and B. Lee
Clinical Consequences of Urea Cycle Enzyme Deficiencies and Potential Links to Arginine and Nitric Oxide Metabolism
J. Nutr., October 1, 2004; 134(10): 2775S - 2782S.
[Abstract] [Full Text] [PDF]